Articles tagged "Liver transplantation"

2020 American Transplant Congress
Hepatocellular Carcinoma Locoregional Therapy: A Comparison of Radiologic Treatment Response and Post-Transplant Pathology
A. J. Hargrove¹, T. Donovan², K. Fisher³, M. Goodenberger⁴, A. Langnas¹, S. Merani¹
¹Department of Surgery, Division of Transplant Surgery, University of Nebraska Medical Center, Omaha, NE, ²Department of Radiology, Division of Interventional Radiology, University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Radiology, Division of Body Imaging, University of Nebraska Medical Center, Omaha, NE
*Purpose: Transplantation or resection is the only potentially curative treatment for Hepatocellular Carcinoma (HCC). Locoregional therapy (LRT) is used exclusively in non-transplant candidates or as…
2020 American Transplant Congress
Comparing Post-Transplant Outcomes in Living and Deceased Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: An Analysis of UNOS Registry
T. Kitajima¹, D. Moonka², S. Yeddula¹, M. Rizzari¹, K. Collins¹, A. Yoshida¹, M. S. Abouljoud¹, S. Nagai¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI
*Purpose: Because of possible short waiting time, living donor liver transplantation (LDLT) for HCC may provide survival benefit compared to deceased donor LT (DDLT). This…
2020 American Transplant Congress
Barriers to Organ Transplantation among Underrepresented Racial and Ethnic Groups
M. Parra
Duke Clinical Research Institute, Durham, NC
*Purpose: To understand how known patient, provider, and system-level barriers to organ transplantation differ by race and ethnicity.*Methods: We searched Pubmed and Scopus for articles…
2020 American Transplant Congress
Renal Safety of Entecavir and Tenofovir with Hepatitis B Immunoglobulin in Liver Transplant Patients
J. Lee¹, E. Kim¹, S. Yang¹, D. Kim², S. Kim¹, J. Park³, H. Choi⁴, B. Kim³, D. Joo¹, M. Kim¹, S. Kim¹, J. Lee¹
¹Department of Transplantation Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ²Department of Surgery, Wonju Severance Hospital, Yonsei University College of Medicine, Wonju, Korea, Republic of, ³Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ⁴Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
*Purpose: Combination of potent nucleos(t)ide analougues (NAs) and hepatitis B immunoglobulin is recommended after liver transplantation for the prevention of hepatitis B virus (HBV) recurrence.…
2020 American Transplant Congress
Impact of Pre-Liver Transplant Cardiovascular Disease Risk Assessment Standardization on Resource Utilization and Recipient Selection
J. Rice¹, D. Hughes¹, J. R. Burton¹, E. D. Pomfret², J. J. Pomposelli², A. V. Ambardekar³, M. Kriss¹
¹Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Aurora, CO, ²Division of Transplant Surgery, University of Colorado School of Medicine, Aurora, CO, ³Division of Cardiology, University of Colorado School of Medicine, Aurora, CO
*Purpose: Cardiovascular disease (CVD) risk assessment (RA) prior to liver transplantation (LT) is a critical aspect of recipient selection, however data on optimal testing is…
2020 American Transplant Congress
Evaluation of Oral Candidiasis Incidence at Large Academic Medical Center in Absence of Pharmacologic Prophylaxis at Discharge
C. Sammons¹, M. Norris², N. Casciello²
¹Hosp of Univ of Pennsylvania, Philadelphia, PA, ²Pharmacy, Hosp of Univ of Pennsylvania, Philadelphia, PA
*Purpose: Oral candidiasis (OC) is a common complication in solid organ transplant recipients. Despite AST guidelines recommending against universal prophylaxis, it has become common practice…
2020 American Transplant Congress
Marginal Not So Marginal Anymore: Time for New Definitions for “Marginal” Allografts in Liver Transplantation?
T. Zhang¹, J. Dunson¹, F. Kanwal², T. Galvan², J. Vierling², C. O'Mahony², J. Goss², A. Rana²
¹Medical Student, Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, TX
*Purpose: We examined time trends in the outcomes of patients who received marginal liver allografts defined on the basis of the Donor Risk Index [DRI]…
2020 American Transplant Congress
The Liver Outcome Monitoring Registry Consortium: Data and Preliminary Outcome Results
J. Case¹, S. Kurian¹, B. Barrick¹, A. Robinson², M. Prentice², C. Marsh¹
¹Scripps Center for Organ and Cell Transplantation, La Jolla, CA, ²United Network for Organ Sharing Research Department, Richmond, VA
*Purpose: The Liver Outcome Monitoring Registry (LOMR) is an online platform for collecting and monitoring liver outcome data of marginal and DCD organs to be…
2020 American Transplant Congress
Management of Pancreatic Cancer after Liver Transplantation: A 27-Year Single-Center Experience
I. A. Ziogas, M. A. Rauf, L. K. Matsuoka, M. I. Montenovo, M. Izzy, S. P. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: The occurrence of de novo cancer after liver transplant (LT) is a leading cause of post-LT mortality and can be partially attributed to the…
2020 American Transplant Congress
Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates
A. Kardashian¹, J. Ge¹, C. McCulloch¹, M. R. Kappus², M. A. Dunn³, A. Duarte-Rojo³, M. L. Volk⁴, R. S. Rahimi⁵, E. C. Verna⁶, D. R. Ganger⁷, D. Ladner⁷, J. L. Dodge¹, B. Boyarsky⁸, M. McAdams-DeMarco⁸, D. L. Segev⁸, J. C. Lai¹
¹UCSF, SF, CA, ²Duke, Durham, NC, ³UPMC, Pittsburgh, PA, ⁴LLU, Loma Linda, CA, ⁵BSWH, Dallas, TX, ⁶Columbia, NY, NY, ⁷Northwestern, Chicago, IL, ⁸JHMI, Baltimore, MD
*Purpose: Frailty is associated with mortality in liver transplant (LT) waitlist candidates. We developed the Liver Frailty Index (LFI) to assess frailty in patients with…